February 16, 2018 07:31 AM EST

Tiny Apricus’ survival strategy nixed for now by FDA rejection of erectile dysfunction therapy, shares crater

John Carroll

Editor & Founder

A little less than two years after tiny, San Diego-based Apricus Biosciences $APRI decided to cut its staff and concentrate the survivors on an erectile …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Tiny Apricus’ survival strategy nixed for now by FDA rejection of erectile dysfunction therapy, shares crater

John Carroll

Editor & Founder

Sign up to read this article for free.

Updated: Eli Lilly wins long-awaited approval for Alzheimer’s drug

Takeda to lay off more employees in Massachusetts

Following a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot

As confidence falls, biopharma companies take precautions with Chinese partnerships, survey finds

Checkpoint Therapeutics refiles PD-L1 drug cosibelimab after FDA rejection

J&J and Legend say Carvykti improved survival in earlier-line multiple myeloma

Tiny Apri­cus’ sur­vival strat­e­gy nixed for now by FDA re­jec­tion of erec­tile dys­func­tion ther­a­py, shares crater

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Up­dat­ed: Eli Lil­ly wins long-await­ed ap­proval for Alzheimer’s drug

Take­da to lay off more em­ploy­ees in Mass­a­chu­setts

Fol­low­ing a piv­otal tri­al fail and lay­offs, Ovid finds it­self in a fa­mil­iar spot

As con­fi­dence falls, bio­phar­ma com­pa­nies take pre­cau­tions with Chi­nese part­ner­ships, sur­vey finds

Check­point Ther­a­peu­tics re­files PD-L1 drug cosi­be­limab af­ter FDA re­jec­tion

J&J and Leg­end say Carvyk­ti im­proved sur­vival in ear­li­er-line mul­ti­ple myelo­ma

Tiny Apricus’ survival strategy nixed for now by FDA rejection of erectile dysfunction therapy, shares crater

Updated: Eli Lilly wins long-awaited approval for Alzheimer’s drug

Takeda to lay off more employees in Massachusetts

Following a pivotal trial fail and layoffs, Ovid finds itself in a familiar spot

As confidence falls, biopharma companies take precautions with Chinese partnerships, survey finds

Checkpoint Therapeutics refiles PD-L1 drug cosibelimab after FDA rejection

J&J and Legend say Carvykti improved survival in earlier-line multiple myeloma